European Companies Search Engine
EU funding (€3,812,883): INnovative Training in Myeloid Regulatory Cell Therapy Hor28 Aug 2019 EU Research and Innovation programme "Horizon"
Overview
Text
INnovative Training in Myeloid Regulatory Cell Therapy
Cell therapy is an active area of immunological research and represents a highly innovative and rapidly expanding sector of pharmaceutical industry. The INsTRuCT Consortium answers an unmet need in the field for postdoctoral researchers experienced in scientifically excellent research and cell therapy development. INsTRuCT draws upon complementary expertise of its academic and industrial partners to offer a unique research and training programme. INsTRuCT proposes 15 distinctive research projects based at European companies or universities recognized for their scientific achievements and innovation. INsTRuCT is structured to promote interdisciplinary and intersectoral cooperation between partners, thereby accelerating pharmaceutical development and clinical application of novel myeloid regulatory cell (MRC)-based therapies. INsTRuCT is a primarily research-based training programme, which will be complemented by theoretical and practical training opportunities. INsTRuCT will encourage a translational view of research, which will be reinforced by intersectoral secondments. Teaching transferrable and communication skills is a high priority for INsTRuCT. ESR will gain a comprehensive overview of the drug development process in Europe as it applies to cell-based therapies; hence, INsTRuCT’s graduates will be fitted for future roles as innovative leaders in the field. INsTRuCT will strengthen interactions between cooperating research groups at junior and senior levels, thereby promoting dissemination of standardized research approaches and data-sharing. Overall, INsTRuCT constitutes an original research and training concept that responds to the specific needs of a growing sector for postdoctoral scientists trained in Basic Immunology and cell therapy development. Consequently, INsTRuCT has a very high impact potential, both in terms of its scientific and technical advancements, and its future contribution to innovation and economic development within the European Union.
Funded Companies:
| Company name | Funding amount |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | €252,788 |
| Institut de Investigacio en Ciencies de La Salut Germans Trias i Pujol | €250,905 |
| Instituto de Salud Carlos III | €250,905 |
| King's College London | €227,379 |
| KLINIKUM DER UNIVERSITAET REGENSBURG | €624,949 |
| MILTENYI BIOTEC B.V. & Co. KG | €277,365 |
| Nantes Universite | €274,802 |
| Ospedale SAN Raffaele Srl | €261,500 |
| Stichting Sanquin Bloedvoorziening | €265,620 |
| The Provost, Fellows Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | €274,684 |
| Universiteit Antwerpen | €245,640 |
| University of Newcastle Upon Tyne | €606,345 |
Source: https://cordis.europa.eu/project/id/860003
The filing refers to a past date, and does not necessarily reflect the current state.